FibroGen Inc (FGEN)
1.12
-0.04
(-3.45%)
USD |
NASDAQ |
Jun 14, 16:00
1.125
0.00 (0.00%)
After-Hours: 20:00
FibroGen Research and Development Expense (Annual): 282.86M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 282.86M |
| December 31, 2022 | 296.79M |
| December 31, 2021 | 387.04M |
| December 31, 2020 | 252.92M |
| December 31, 2019 | 209.26M |
| December 31, 2018 | 235.84M |
| Date | Value |
|---|---|
| December 31, 2017 | 196.52M |
| December 31, 2016 | 187.21M |
| December 31, 2015 | 214.09M |
| December 31, 2014 | 150.79M |
| December 31, 2013 | 85.71M |
| December 31, 2012 | 74.22M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
209.26M
Minimum
2019
387.04M
Maximum
2021
285.78M
Average
282.86M
Median
2023
Research and Development Expense (Annual) Benchmarks
| Regeneron Pharmaceuticals Inc | 4.439B |
| Annovis Bio Inc | 38.79M |
| Vertex Pharmaceuticals Inc | 3.163B |
| Enanta Pharmaceuticals Inc | 163.52M |
| Nanoviricides Inc | 6.392M |